Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-41704 __________________________________ Fortrea Holdings Inc. (Exac ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.82%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.12, delivering a surprise of -25%.Over the last four quarters, the com ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnshul Thakral - CEO and DirectorDavid Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorJailendra Singh - Managing DirectorJill McConnell - CFOTracy Krumme - SVP of Investor RelationsConference Call ParticipantsAnn Hynes - AnalystEric Coldwell - Senior Research AnalystJustin Bowers - Biopharma Services Senior Equity Research AnalystMax Smock - AnalystPatrick Donnelly - Managing Director and ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnshul Thakral - CEO and DirectorDavid Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorJailendra Singh - Managing DirectorJill McConnell - CFOTracy Krumme - SVP of Investor RelationsConference Call ParticipantsAnn Hynes - AnalystEric Coldwell - Senior Research AnalystJustin Bowers - Biopharma Services Senior Equity Research AnalystMax Smock - AnalystPatrick Donnelly - Managing Director and ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker9Good day. Thank you for standing by. Welcome to the Fortrea Q4 and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question ...

Learn more at fortrea.com. ©2026 Fortrea Inc. All rights reserved. Fortrea Q4'2025 Earnings presentation Q4 & FY 2025 Earnings Presentation 02.26.2026 Nasdaq: FTRE Learn more at fortrea.com. ©2026 Fortrea Inc. All rights reserved. Fortrea Q4'2025 Earnings presentation FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements Disclosure. Certain information in this presentation contains "forward-looking" statements. You should not place undue reliance on these statements. Forward- l ...

Exhibit 99.1 Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full ‑ year cost savings exceeded previously communicated targets Highlights: DURHAM, N.C., February 26, 2026 — Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the fourth quarter and full year ended December 31, 2025. "We finished 2025 with ...

Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EB ...

此举旨在加强高管团队对早期临床开发的关注，并深化与客户的医疗和科学合作北卡罗来纳州达勒姆, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 全球领先的合同研究组织 (CRO) Fortrea (Nasdaq: FTRE)（以下简称“公司”）今日宣布扩充其高管团队。此前兼任 Fortrea 首席医疗官 (CMO) 和临床药理服务 (CPS) 总裁的 Oren Cohen 医学博士，现专注于其 CMO 职责，主要负责 Fortrea 所有业务的医疗战略、科学领导、伦理和治理监督。Scott Dove 博士加入 Fortrea，担任临床药学服务总裁，负责 Fortrea 在其全球临床研究机构网络中的早期临床开发解决方案。Cohen 和 Dove 均是 Fortrea 的执行委员会成员。 首席执行官 Anshul Thakral 表示：“Scott 加入 Fortrea 团队，同时 Oren 完全专注于开发过程中的医学与科学事务，这对客户而言是一项双赢举措。Oren 将与我们在临床开发各阶段的业务负责人紧密协作，深化其与客户的关系。他更早地参与科学研讨，与公司医师及治疗领域领导者密切协作，共同应对 ...

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clientsDURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strate ...